ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024. Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day. To schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the electroCore Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Gol ...

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.90%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.38, delivering a surprise of 2.56%.Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ECOR Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ ...

electroCore Announces Third Quarter 2024 Financial Results Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, NJ, November 13, 2024 (GLOBE NEWSWIRE) – electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights · Eighth consecuti ...

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 4 ...

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men’s Health Magazine Tech Award for a pioneering wellness device recognized for innovation and excellence. The award celebrates groundbreaking advancements in health and technology and highlights products that significantly impact men’s health and wellness. A ...

electroCore, Inc. (ECOR) shares soared 6% in the last trading session to close at $13.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 61.1% gain over the past four weeks.The recent rise in the stock price can be attributed to investors’ optimism about the financial performance of electroCore’s flagship product, gammaCore Sapphire, in the upcoming third-quarter 2024 results. The company also has two other products in its comme ...

electroCore, Inc. (ECOR) shares rallied 11.7% in the last trading session to close at $8.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 24.5% gain over the past four weeks.The sudden rise in the stock price can be attributed to the investors’ positive mindset regarding the financial performance of electroCore’s flagship product, gammaCore Sapphire, in the upcoming earnings results. It is a prescription m ...

. ● . electroCore to Participate at LD Micro Main Event VXII October 14, 2024 8:00 AM EDT | Source: LD Micro Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the LD Micro Main Event XVII on Tuesday, October 29 at 4:30 p.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Dan Goldberger, CEO will be representing the company and will be avail ...